Edition:
United Kingdom

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

148.01USD
20 Apr 2018
Change (% chg)

$-21.66 (-12.77%)
Prev Close
$169.67
Open
$168.53
Day's High
$168.53
Day's Low
$147.25
Volume
369,067
Avg. Vol
230,980
52-wk High
$195.97
52-wk Low
$59.59

Latest Key Developments (Source: Significant Developments)

Sage Therapeutics Reports Positive Results From Phase 2 Placebo-Controlled Trial Of Sage-217 In Major Depressive Disorder
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Sage Therapeutics Inc ::SAGE THERAPEUTICS REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 2 PLACEBO-CONTROLLED TRIAL OF SAGE-217 IN MAJOR DEPRESSIVE DISORDER.SAGE THERAPEUTICS - SAGE-217 MET PRIMARY ENDPOINT AND PROVIDED RAPID, DURABLE EFFECTS THROUGH 2-WEEK TREATMENT PERIOD AND ADDITIONAL 4-WEEK FOLLOW-UP.SAGE THERAPEUTICS - PHASE 2 TRIAL OF SAGE-217​ ‍WELL-TOLERATED.SAGE THERAPEUTICS INC - DATA FROM PHASE 2 STUDY SUPPORT FURTHER DEVELOPMENT OF SAGE-217 FOR MDD AND RELATED DISORDERS.SAGE THERAPEUTICS - SAGE-217 DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT MEAN REDUCTION IN HAM-D SCORE COMPARED TO PLACEBO AT 15 DAYS​.SAGE THERAPEUTICS INC - SAGE-217 HAD NO SERIOUS OR SEVERE ADVERSE EVENTS IN PHASE 2 STUDY.SAGE THERAPEUTICS - ALL SECONDARY ENDPOINTS WERE CONSISTENT WITH PRIMARY ENDPOINTS AT DAY 15 OF TRIAL OF SAGE-217.  Full Article

Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Sage Therapeutics Inc -:SAGE THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE.  Full Article

Sage Therapeutics announces proposed public offering of common stock
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Sage Therapeutics Inc :Sage Therapeutics announces proposed public offering of common stock.Sage Therapeutics Inc - ‍has commenced an underwritten public offering of $300.0 million of its common stock​.  Full Article

Sage Therapeutics announces Brexanolone achieves primary endpoints
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sage Therapeutics Inc ::Announces Brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression.Statistically significant mean reduction in HAM-D score compared to placebo at 60 hours demonstrated in both trials​.Brexanolone was generally well tolerated and showed a similar safety profile as seen in earlier studies​.Brexanolone achieved primary endpoint in both trials​.In each trial, 1 patient experienced serious adverse event; neither required hospitalization, 1 deemed not to be study-drug related​.Sage plans to file a New Drug Application (NDA) with U.S. Food and Drug Administration in 2018 for Brexanolone​.  Full Article

Sage Therapeutics announces qtrly loss per share $1.97‍​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Sage Therapeutics Inc :Sage Therapeutics announces third quarter 2017 financial results and provides pipeline update.Qtrly loss per share $1.97‍​.  Full Article

Sage Therapeutics advances SAGE-217
Monday, 13 Feb 2017 

Sage Therapeutics Inc - : Sage Therapeutics advances SAGE-217 into placebo-controlled phase 2 clinical trial in major depressive disorder . SAGE-217 was found to be generally well-tolerated with no serious adverse events or discontinuations reported .Statistically significant mean change from baseline was observed by day 2 of study.  Full Article

Sage Therapeutics starts Phase 2 clinical development for SAGE-217 in movement disorders
Tuesday, 13 Dec 2016 

Sage Therapeutics Inc : Essential tremor study is anticipated to report results in second half of 2017 . Sage Therapeutics announces initiation of Phase 2 clinical development for SAGE-217 in movement disorders . Sage Therapeutics - top-line results from part a open-label study in Parkinson's disease are expected in first half of 2017 .Also plans to initiate Phase 2 clinical trials of SAGE-217 in two mood disorders.  Full Article

Sage Therapeutics Q2 EPS ($1.08)
Tuesday, 9 Aug 2016 

Sage Therapeutics Inc : Sage Therapeutics announces second quarter 2016 financial results and provides corporate update .Qtrly loss per share $1.08.  Full Article

Sage Therapeutics says completed enrollment for Phase 2 trial of Sage-547
Thursday, 26 May 2016 

Sage Therapeutics Inc :SAGE THERAPEUTICS announces completion of enrollment for phase 2 proof-of-concept trial of sage-547 in severe postpartum depression.  Full Article

Why Oppenheimer Global fund is focusing on biotech as rates rise

NEW YORK The recent volatility in the global stock market may make some investors feel queasy, but it is providing a buying opportunity in biotechnology stocks.